Skip to main content
. Author manuscript; available in PMC: 2024 Jul 1.
Published in final edited form as: Ann Oncol. 2023 Apr 25;34(7):615–625. doi: 10.1016/j.annonc.2023.04.006

Figure 4. KIT ATP-BP and A-loop mutations in ctDNA are prognostic of TKI activity in GIST.

Figure 4.

Regorafenib had greater efficacy than avapritinib in patients with an ATP-BP mutation (A), a KIT A-loop mutation (B), and those with both ATP-BP and A-loop mutations (C). (D) Avapritinib improved PFS in the absence of a KIT mutation, while regorafenib was relatively unaffected. Ava, avapritinib; CI, confidence interval; mPFS, median progression-free survival; NE, not estimable; neg, negative; pos, positive; Reg, regorafenib.